Memantine and Post-mastectomy Neuropathic Pain

• Status: Not yet recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to evaluate if memantine administered for four weeks starting two weeks before surgery induces a decrease in pain intensity at 3 months post-mastectomy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Patient ≥18 years,

• Patient with a diagnosis of breast cancer, programmed for mastectomy with or without axillary dissection and neoadjuvant chemotherapy,

• Patient able to understand and willing to follow the study protocol,

• Acceptance to give a written consent.

Exclusion Criteria:

• Patient with a contraindication to memantine administration (hypertension, severe cardiac or hepatic insufficiency, stroke),

• Patient with diabetes (type I and II),

• Patient with renal insufficiency,

• Patient with drug treatments evaluated by the investigator to be not compatible with the trial,

• Patient treated with specific drugs (amantadine, ketamine, dextromethorphan, L-Dopa, dopaminergic, anticholinergic agonists, barbituric, neuroleptic, IMAO, antispastic agents, dantrolen or baclofen, phenytoin, cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine, hydrochlorothiazide, warfarine),

• Patient with alcohol addiction,

• Epileptic patient or history of epileptic seizure or convulsions,

• Pregnant or nursing woman,

• Patient with a cooperation and an understanding that does not allow for a strict compliance under the conditions set out in the protocol,

• Patient participating in another clinical trial, or being in an exclusion period, or having received a total amount of compensation exceeding 4500 euros over the 12 months preceding the start of the trial,

• Patient benefiting from a legal protection measure (curatorship, guardianship, protection of justice...),